Passage BIO (PASG) Cash from Financing Activities (2019 - 2025)
Passage BIO (PASG) posted quarterly Cash from Financing Activities of $9000.0 for Q4 2025, down 80.85% year-over-year from $47000.0 in Q4 2024, and down 80.85% quarter-over-quarter from $47000.0 in Q4 2024.
Passage BIO (PASG) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Passage BIO's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $9000.0 for Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 80.85% year-over-year to $9000.0; the TTM figure through Dec 2025 stood at $56000.0 (down 99.37% YoY), while the FY2025 annual figure was $23000.0, down 99.74% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $9000.0, down from $47000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $165.6 million in Q1 2021, with the low at -$588000.0 in Q4 2022.
- The 5-year median for Cash from Financing Activities is $47000.0 (2024), against an average of $13.4 million.
- The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities soared 132.77% in 2021, then tumbled 1027.27% in 2022.
- Passage BIO's Cash from Financing Activities stood at $455000.0 in 2021, then slumped by 229.23% to -$588000.0 in 2022, then soared by 107.82% to $46000.0 in 2023, then gained by 2.17% to $47000.0 in 2024, then sank by 80.85% to $9000.0 in 2025.
- Business Quant data shows PASG's Cash from Financing Activities at $9000.0 in Q4 2025, $47000.0 in Q4 2024, and $85000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Mar 31, 2024 | 8.74 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Dec 31, 2023 | 46,000.00 |
| Dec 31, 2023 | 46,000.00 |
| Dec 31, 2022 | -588,000.00 |
| Dec 31, 2022 | -588,000.00 |
| Sep 30, 2022 | -408,000.00 |
| Sep 30, 2022 | -408,000.00 |
| Jun 30, 2022 | -406,000.00 |
| Jun 30, 2022 | -406,000.00 |
| Mar 31, 2022 | 49,000.00 |
| Mar 31, 2022 | 49,000.00 |
| Dec 31, 2021 | 455,000.00 |
| Dec 31, 2021 | 455,000.00 |